Text Size

Use of Multiphoton Microscopy in the Diagnosis of Cancer (MPM)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by Weill Medical College of Cornell University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:
NCT00652210
First received: March 31, 2008
Last updated: November 4, 2010
Last verified: November 2010
History of Changes
  Purpose

Multiphoton microscopy (MPM) has been shown to be able to image tissue at a cellular level. Our project will initially evaluated the ability of MPM imaging to distinguish normal bladder urothelium from atypical and malignant urothelium in the ex vivo setting. After development of sufficient criteria, we plan to develop an endoscopic bladder probe that will provide a non-invasive means to image the interior of the bladder at the cellular level, which would provide direct evidence of the presence of tumor without a biopsy. After exhibiting usefulness of MPM imaging for bladder cancer, we will look at other organs beginning with the colon.


Condition Intervention Phase
Bladder Cancer
Prostate Cancer
 Other: Multiphoton microscopy
 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Use of Multiphoton Microscopy in the Diagnosis of Cancer

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Weill Medical College of Cornell University:

Primary Outcome Measures:
  • After several delays, the multiphoton microscope has been delivered to Weill Cornell Medical College. We have been using this time to set-up and fine tune the multiphoton microscope. As of current, no negative events have occurred. [ Time Frame: 10/14/2007 to 2/15/2008 ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: October 2007
Estimated Study Completion Date: March 2010
Estimated Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Multiphoton microscopy
    Use of multiphoton microscopy to diagnose cancer
Detailed Description:

Same as above

  Eligibility

Ages Eligible for Study:   21 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Anyone who presents with bladder and/or prostate cancer
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00652210

Contacts
Contact: Ming-Ming Lee, B.A. (212) 746-5467 mil2022@med.cornell.edu

Locations
United States, New York
Weill Cornell Medical College Recruiting
New York, New York, United States, 10065
Principal Investigator: Douglas S. Scherr, M.D.            
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Principal Investigator: Douglas S Scherr, M.D. Weill Medical College of Cornell University
  More Information

No publications provided

Responsible Party: Douglas S. Scherr/Clinical Director of Urologic Oncology, Weill Cornell Medical College
ClinicalTrials.gov Identifier: NCT00652210     History of Changes
Other Study ID Numbers: 0506007919
Study First Received: March 31, 2008
Last Updated: November 4, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Weill Medical College of Cornell University:
Bladder cancer
prostate cancer
multiphoton microscopy

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Prostatic Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
 Urinary Bladder Diseases
Urologic Diseases
Genital Neoplasms, Male
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on May 22, 2013